Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophosphamide-based regimens

European Journal of Cancer

Volumn 45, Issue 5, 2009, Pages 814-818

  Ridola, Vita ^a,b   Fawaz, Oumaya ^a   Aubier, Françoise ^c   Bergeron, Christophe ^d   de Vathaire, Florent ^e   Pichon, Fabienne ^f   Orbach, Daniel ^g   Gentet, Jean Claude ^h   Schmitt, Claudine ⁱ   Dufour, Christelle ^a   Oberlin, Odile ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CATHOLIC UNIVERSITY   (Italy)

^c Department of Oncology   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSERM   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g INSTITUT CURIE   (France)

^h TIMONE HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Cyclophosphamide; Fertility; Gonads; Ifosfamide; Long term sequelae; Male; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; ARTICLE; AZOOSPERMIA; BONE MARROW TOXICITY; CANCER SURVIVOR; CHILDHOOD CANCER; COMPARATIVE STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FOLLITROPIN BLOOD LEVEL; GONADAL DISEASE; HUMAN; INFERTILITY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALE STERILITY; NEPHROTOXICITY; OLIGOSPERMIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEMEN ANALYSIS; TESTIS FUNCTION; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL MARKERS; CHILD; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUTEINIZING HORMONE; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS; SARCOMA; SURVIVORS; TESTICULAR DISEASES; TESTIS; TESTOSTERONE;

EID: 61449215974     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.002     Document Type: Article

References (29)

1. Aubier F., Flamant F., Brauner R., Caillaud J.M., Chaussain J.M., and Lemerle J. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol 7 (1989) 304-309
2. Heikens J., Behrendt H., Adriaanse R., and Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Cancer 78 (1996) 2020-2024
3. Kenney L.B., Laufer M.R., Grant F.D., Grier H., and Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 91 (2001) 613-621
4. Mackie E.J., Radford M., and Shalet S.M. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 27 (1996) 74-78
5. Waring A.B., and Wallace W.H. Subfertility following treatment for childhood cancer. Hosp Med 61 (2000) 550-557
6. Meistrich M.L., Finch M., da Cunha M.F., Hacker U., and Au W.W. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 42 (1982) 122-131
7. Jensen T.K., Andersson A.M., Hjollund N.H., Scheike T., Kolstad H., Giwercman A., et al. Inhibin B as a serum marker of spermatogenesis: correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men. J Clin Endocrinol Metab 82 (1997) 4059-4063
8. Lahteenmaki P.M., Arola M., Suominen J., Salmi T.T., Andersson A.M., and Toppari J. Male reproductive health after childhood cancer. Acta Paediatr 97 (2008) 935-942
9. Brade W., Seeber S., and Herdrich K. Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother Pharmacol 18 Suppl. 2 (1986) S1-S9
10. Crist W.M., Anderson J.R., Meza J.L., Fryer C., Raney R.B., Ruymann F.B., et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19 (2001) 3091-3102
11. Ruymann F.B., Vietti T., Gehan E., Wiener E., Wharam M., Newton Jr. W.A., et al. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol 17 (1995) 331-337
12. Kalifa C., Razafindrakoto H., Vassal G., Contesso G., Vanel D., Edeline V., et al. Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute. Cancer Treat Res 62 (1993) 347-349
13. Le Deley M.C., Guinebretiere J.M., Gentet J.C., Pacquement H., Pichon F., Marec-Berard P., et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43 (2007) 752-761
14. Oberlin O., Habrand J.L., Zucker J.M., Brunat-Mentigny M., Terrier-Lacombe M.J., Dubousset J., et al. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10 (1992) 1407-1412
15. Stevens M.C. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 6 (2005) 77-84
16. Flamant F., Rodary C., Rey A., Praquin M.T., Sommelet D., Quintana E., et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 34 (1998) 1050-1062
17. Aubier F., Patte C., de Vathaire F., Tournade M.F., Oberlin O., Sakiroglu O., et al. Male fertility after chemotherapy during childhood. Ann Endocrinol (Paris) 56 (1995) 141-142
18. Ben Arush M.W., Solt I., Lightman A., Linn S., and Kuten A. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 17 (2000) 239-245
19. Bramswig J.H., Heimes U., Heiermann E., Schlegel W., Nieschlag E., and Schellong G. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65 (1990) 1298-1302
20. Meistrich M.L., Wilson G., Brown B.W., da Cunha M.F., and Lipshultz L.I. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 70 (1992) 2703-2712
21. Muller H.L., Klinkhammer-Schalke M., Seelbach-Gobel B., Hartmann A.A., and Kuhl J. Gonadal function of young adults after therapy of malignancies during childhood or adolescence. Eur J Pediatr 155 (1996) 763-769
22. Papadakis V., Vlachopapadopoulou E., Van Syckle K., Ganshaw L., Kalmanti M., Tan C., et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol 32 (1999) 366-372
23. Shafford E.A., Kingston J.E., Malpas J.S., Plowman P.N., Pritchard J., Savage M.O., et al. Testicular function following the treatment of Hodgkin's disease in childhood. Br J Cancer 68 (1993) 1199-1204
24. Rivkees S.A., and Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259 (1988) 2123-2125
25. Longhi A., Macchiagodena M., Vitali G., and Bacci G. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 25 (2003) 292-296
26. Howell S.J., and Shalet S.M. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr (2005) 12-17
27. Marmor D., and Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia 27 (1995) 99-106
28. Garolla A., Pizzato C., Ferlin A., Carli M.O., Selice R., and Foresta C. Progress in the development of childhood cancer therapy. Reprod Toxicol 22 (2006) 126-132
29. Williams D., Crofton P.M., and Levitt G. Does ifosfamide affect gonadal function?. Pediatr Blood Cancer 50 (2008) 347-351